Trinity Capital Inc. Stock Price, News & Analysis

Trinity Capital (Nasdaq: TRIN) announced on December 4, 2025 a commitment of equipment financing to Sortera Technologies, an Indiana-based company that uses AI, data analytics, and advanced sensors to upcycle and sort complex scrap metals at industrial scale. The financing is intended to support Sortera's expansion of automated sortation facilities to supply high-quality upcycled alloys to manufacturers while lowering costs and reducing waste.

Sortera positions its patented AI to classify metals by size, shape, texture, and alloy composition and targets opportunity in the large metals and recycling markets; Trinity framed the relationship as strategic for Sortera's next phase of growth.

Trinity Capital (Nasdaq: TRIN) announced a commitment of growth capital to Kinetic, a workers' compensation Managing General Underwriter, to accelerate expansion of its workplace injury management technology.

Kinetic pairs a proprietary safety wearable with Claims Navigator, an AI-driven claims intelligence system that detects emerging risks in real time, automates follow-up, and guides policyholders to close claims faster and reduce costs. Trinity said the capital will support Kinetic's buildout of an end-to-end claims management software layer and broader commercial growth.

Trinity Capital (Nasdaq: TRIN) announced a $45 million growth capital commitment to Rapid Micro Biosystems (Nasdaq: RPID) to support scaling of the Growth Direct platform and global commercial expansion.

The funding is designated to accelerate manufacturing scale, fund product cost reductions, improve service productivity, and drive gross margin expansion, with the stated goal of strengthening Rapid Micro's financial position and supporting long-term revenue growth and shareholder value.

Trinity Capital (Nasdaq: TRIN) reported third quarter 2025 results on November 5, 2025, with record funding and growth in key metrics.

Key figures: Record funding $471.0M (gross investments funded ~$470.6M), total investment income $75.6M (+22.3% YoY), net investment income $37.0M ($0.52 per basic share, +25.9% YoY), NAV $998.3M or $13.31 per share (NAV +31.9% YoY), total commitments $773.0M, and leverage ~119%.

The company raised capital via its equity ATM (~5.32M shares; net $83.0M) and issued $125.0M of 6.750% notes due 2030; quarterly dividend was $0.51 per share.

Trinity Capital (Nasdaq: TRIN) announced on October 23, 2025 that it provided equipment and asset financing to Bobbie, a U.S.-based, mom-founded organic infant formula company. The funding will support scaling operations at Bobbie's Ohio facility and accelerate national growth for its American-manufactured, USDA-certified organic whole milk infant formula launched in April 2025.

The partnership aims to increase domestic production resilience and broaden access to Bobbie's subscription-based distribution of organic infant nutrition.

Trinity Capital (Nasdaq: TRIN) announced a $15 million growth capital commitment to Kard on October 21, 2025 to accelerate expansion of Kard's commerce media network.

Kard powers merchant-funded, API-first rewards for banks, fintechs and loyalty programs, reaching tens of millions of consumers and processing over $10 billion in transactions each month. Trinity said the funding will help Kard scale operations and expand into new markets while Kard will continue using aggregated spend data and AI-driven personalization to drive incremental merchant growth and strengthen issuer loyalty.

Trinity Capital (Nasdaq: TRIN) committed $130 million in growth capital to Candel Therapeutics (Nasdaq: CADL) on October 14, 2025 to support development of viral immunotherapies.

The funding is earmarked to support clinical development of CAN-2409 and pre-commercial and launch readiness activities for CAN-2409 in prostate cancer pending regulatory approval. Candel's pipeline includes CAN-2409 and CAN-3110 targeting solid tumors (prostate, pancreatic, lung, brain).

Candel has received multiple FDA designations: RMAT for localized prostate cancer, Fast Track for localized prostate and non-small cell lung cancer, and dual Fast Track and Orphan Drug designations for pancreatic and brain cancer programs.

Trinity Capital (Nasdaq: TRIN) reported that it originated $773 million of new commitments in Q3 2025, bringing year-to-date new commitments to $1.5 billion through the first three quarters of 2025.

Q3 2025 investments funded totaled approximately $471 million (comprised of $381M secured loans, $57M equipment financings, $33M warrants/equity). Q3 proceeds from repayments and exits were ~$255 million. For the first three quarters, investments funded were ~$1.1 billion and proceeds totaled ~$607 million.

The company will release complete Q3 2025 financial results and host a conference call on November 5, 2025 at 12:00 p.m. ET.

Trinity Capital (Nasdaq: TRIN) appointed Paul D'Agrosa as Managing Director of Life Sciences, based in Denver, effective Oct. 8, 2025.

Mr. D'Agrosa joins to help expand Trinity's Life Sciences platform across new U.S. markets; he brings more than a decade of experience in loan origination, business development, and relationship management. His prior roles include Managing Director at Horizon Technology Finance, where he helped originate more than $140 million in new loan commitments within his first 15 months, and 10 years at Silicon Valley Bank in relationship and credit roles.

The company framed the hire as a step to strengthen life‑sciences lending and source new opportunities across Medtech, Healthtech, Biotech, and Diagnostics/Tools.